Multivalent Atezolizumab-Liposome Conjugates as Active Immunotherapeutic Platforms for Enhanced PD-L1 Blockade in Melanoma
International Journal of Nanomedicine · 2026-01 · Volume 21 · 1-22
DOI: 10.2147/ijn.s561111 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Nanomedicine, 2026-01. Verfasst von Ziyun Cheng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Precision Medicine in Oncology (PrMiO) and Nanomedicine Innovation Center Erasmus (NICE), Department of Pathology, Erasmus MC Cancer Institute, Erasm…. Hauptthemen laut MEDLINE: Liposomes, Melanoma, B7-H1 Antigen, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Precision Medicine in Oncology (PrMiO) and Nanomedicine Innovation Center Erasmus (NICE), Department of Pathology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, the Netherlands.
- Laboratory of Tumor Immunology, Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, the Netherlands.
- Department of Pathology, Erasmus MC, Rotterdam, the Netherlands.
- Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, the Netherlands.
ORCID-Profile: Ziyun Cheng, Mohamadreza Amin, Mandy van Brakel, Andrea Sacchetti, Robbert Q Kim, Ann L B Seynhaeve, Reno Debets, Timo L M Ten Hagen
Zitieren
APA
Cheng, Z., Amin, M., van Brakel, M., Sacchetti, A., Kim, R. Q., Seynhaeve, A. L. B., Debets, R., & Ten Hagen, T. L. M. (2026). Multivalent Atezolizumab-Liposome Conjugates as Active Immunotherapeutic Platforms for Enhanced PD-L1 Blockade in Melanoma. International Journal of Nanomedicine, Volume 21, 1-22. https://doi.org/10.2147/ijn.s561111
Vancouver
Cheng Z, Amin M, van Brakel M, Sacchetti A, Kim RQ, Seynhaeve ALB, et al. Multivalent Atezolizumab-Liposome Conjugates as Active Immunotherapeutic Platforms for Enhanced PD-L1 Blockade in Melanoma. International Journal of Nanomedicine. 2026;Volume 21:1-22. doi:10.2147/ijn.s561111
BibTeX
@article{Cheng2026,
author = {Cheng, Ziyun and Amin, Mohamadreza and van Brakel, Mandy and Sacchetti, Andrea and Kim, Robbert Q and Seynhaeve, Ann L B and Debets, Reno and Ten Hagen, Timo L M},
title = {Multivalent Atezolizumab-Liposome Conjugates as Active Immunotherapeutic Platforms for Enhanced PD-L1 Blockade in Melanoma},
journal = {International Journal of Nanomedicine},
year = {2026},
volume = {Volume 21},
pages = {1--22},
doi = {10.2147/ijn.s561111}
}
EUVIMED